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Abstract
Background—The CpG Island Methylator Phenotype (CIMP) represents a subset of colorectal 
cancers (CRCs) characterized by widespread aberrant DNA hypermethylation at select CpG 
islands. The risk factors and environmental exposures contributing to etiologic heterogeneity 
between CIMP and non-CIMP tumors are not known.
Methods—We measured the CIMP status of 3,119 primary population-based CRC tumors from 
the multinational Colon Cancer Family Registry. Etiologic heterogeneity was assessed by a case-
case study comparing risk factor frequency of CRC cases with CIMP and non-CIMP tumors using 
logistic regression to estimate the case-case odds ratio (ccOR).
Results—We found associations between tumor CIMP status and MSI-H (ccOR=7.6), BRAF 
V600E mutation (ccOR=59.8), proximal tumor site (ccOR=9) (all p<0.0001), female sex 
(ccOR=1.8; 95% CI=1.5-2.1), older age (ccOR=4.0 comparing over 70 years vs under 50; 95% 
CI=3.0-5.5) and family history of CRC (ccOR=0.6, 95% CI=0.5-0.7). While use of NSAIDs 
varied by tumor CIMP status for both males and females (p=0.0001 and p=0.02, respectively), use 
of multi-vitamin or calcium supplements did not. Only for female CRCs was CIMP status 
associated with increased pack-years of smoking (trend p < 0.001) and body mass index (BMI) 
(trend p = 0.03).
Conclusions—The frequency of several CRC risk factors varied by CIMP status, and the 
associations of smoking and obesity with tumor subtype were evident only for females.
Impact—Differences in the associations of a unique DNA methylation-based subgroup of CRC 
with important lifestyle and environmental exposures increase understanding of the molecular 
pathologic epidemiology of this heavily methylated subset of CRCs.
Keywords
CpG island methylator phenotype; CIMP; Colon Cancer Family Registry; DNA methylation; 
colorectal cancer; KRAS; BRAF; MSI
Introduction
Human colorectal cancer (CRC) is a worldwide heath concern through being a substantial 
cause of morbidity and mortality. In 2014 there will be an estimated 136,830 new cases of 
colon and rectal cancers in the United States, and about 50,000 deaths (1). People with 
Lynch Syndrome carry germline mutations in mismatch repair genes, primarily MLH1, 
MSH2, MSH6 and PMS2, and are predisposed to colorectal cancer. However, Lynch 
Syndrome only accounts for 2-5% of all CRCs (reviewed in (2)). Most CRCs are thought to 
result from the accumulation of somatic genetic (3-5) and epigenetic alterations (reviewed in 
(6,7)) often associated with gender, age, diet, lifestyle habits, and environmental exposures 
(8-15). The majority of non Lynch syndrome CRCs are located in the distal (descending left) 
colon and rectum and are enriched for KRAS mutations. In contrast, approximately 15% of 
CRCs are predominantly located in the proximal (ascending, right colon) of older age 
females with enrichment for BRAFV600E mutations, high levels of microsatellite instability 
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(MSI-H), MLH1 epigenetic silencing and the CpG Island Methylator Phenotype (CIMP) 
(16-23).
CIMP tumors were first identified in 1999 by Toyota and colleagues (22) and are thought to 
develop via the serrated neoplasia pathway (17,24). Using MethyLight technology, we 
identified CIMP from a screen of 195 gene loci, and presented a five-gene diagnostic panel 
to identify CIMP tumors: CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 (23). Using 
this panel, we showed that CIMP tumors are preferentially located in the proximal colon, 
and are associated with the BRAFV600E mutation, MSI-H, increasing age, female gender and 
overall improved patient outcome (23). CIMP has also been described in recent reports 
using genome-scale technologies (25-28).
The associations of CRC with environmental exposures are well documented. The risk of 
CRC is positively associated with smoking, alcohol use, obesity and physical inactivity. A 
recent report of genome-scale DNA methylation in normal colorectal tissues suggests that in 
women, obesity and smoking increase DNA methylation at genes hypermethylated in 
cancer, but that the use of aspirin and hormone replacement therapies is correlated with a 
reduction in DNA hypermethylation (29).
In this study, we sought to confirm previous associations for colorectal CIMP tumors and 
evaluate whether the distributions of known CRC risk factors differ in CIMP and non-CIMP 
tumors, including family CRC history, physical activity, smoking history, history of alcohol 
use, use of non-steroidal anti-inflammatory drugs (NSAID's) and body mass index (BMI). 
We used the resources of the Colon Cancer Family Registry, an international, multi-
institutional consortium, and performed CIMP assays on 3,119 population-based primary 
CRCs. Accompanying these samples are a rich data resource of family history, and the level 
of use/intake of the known CRC risk factors. We evaluated etiological heterogeneity of these 
risk factors using a case-case study, directly comparing the distribution of known CRC risk 
factors between CIMP and non-CIMP tumor subtypes.
Materials and Methods
Study population
Data for this study were obtained through the Colon Cancer Family Registry (C-CFR), a 
National Cancer Institute funded registry of CRC cases, family members and population-
based controls, which utilized standardized methods for data collection and genotyping. 
Detailed information about the C-CFR can be found elsewhere (30) and at coloncfr.org. 
Recruitment at individual C-CFR sites was described previously (30). Participants for this 
study were recruited from six centers: the University of Southern California (USC) 
Consortium (Arizona, Colorado, New Hampshire, Minnesota, North Carolina, and Los 
Angeles, California), University of Hawaii (Honolulu), Fred Hutchinson Cancer Research 
Center (FHCRC, Seattle, WA), Mayo Clinic (Rochester, MN), Cancer Care Ontario 
(Toronto, Canada), and University of Melbourne (Victoria, Australia) using population-
based ascertainment strategies. All centers except FHCRC oversampled case probands with 
first-degree relatives reporting CRC, or CRC case probands diagnosed under age 50 to target 
families with increased CRC risk. First-degree and some second-degree relatives with CRC 
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were also recruited from families with multiple CRC cases. In this study, we included only 
CRC cases recruited from 1997- 2002 (30), who signed a written informed consent and 
completed the risk factor questionnaire (RFQ) within 5 years of their CRC diagnosis.
Risk factor and Clinical data
We obtained risk factor data from the completed RFQs. Age at the time of enrollment was 
categorized as a three-category variable: ≤ 50, 51-69 and ≥ 70 years. Family history of CRC 
was self-reported and was considered positive if the case reported CRC in one or more first-
degree family members (e.g. parents, siblings or children). Cigarette smoking pack-years 
was estimated by multiplying the average reported cigarettes smoked per day times the total 
years of smoking and was categorized with never-smokers as the referent group. BMI was 
categorized into three groups based on WHO criteria for overweight and obesity: 18-24.9, 
25-29.9 and ≥30 kg/m2.
The average weekly hours of physical activity was derived for each of 10 common activities 
within three age periods during adulthood (20-29, 30-49 and >=50 years). Average mode-
specific minutes per week, computed using responses to total number of years and months 
the activity was conducted and its typical duration per week, was multiplied by the mode’s 
average MET cost (31) and summed within age categories to derive total MET-hours per 
week during each age category. To reflect lifetime average physical activity, we calculated 
the mean average MET-hours of all relevant age categories. Adulthood average met-hours 
per week was grouped by quartiles: 0-5.7, 5.8-14.5, 14.6-30.8, >30.8.
Alcohol use was queried for the same three age groups as physical activity, with total drinks 
classified as 0, 1 or > 1 per week.
Supplement intake was a three-level variable (current user/former user/non-user) with a 
‘user’ answer indicating ever use ≥2 times/week for more than a month and use within one 
year prior to cancer diagnosis. NSAID use was coded as ‘user’ if the subject used either 
aspirin or ibuprofen over the same time period and ‘non-user’ if neither was used. Former 
users were users who had stopped using supplement or NSAID more than one year prior to 
cancer diagnosis.
Hormone replacement therapy (HRT) use was coded as yes if the subject answered ‘yes’ to 
the question “have you ever used a pill or patch form of hormone replacement therapy for 
six months or longer” for any hormone replacement preparation (estrogen only or estrogen + 
progesterone).
Tumor site was abstracted from pathology reports and/or state or provincial cancer registries 
and coded using International Classification of Diseases for Oncology, third edition codes. 
Tumors were labeled as proximal colon if located in the cecum, ascending colon, hepatic 
flexure, transverse colon and splenic flexure. Tumors were labeled as distal colon if located 
in the descending colon, sigmoid colon and the region overlapping the colon and rectum. 
Tumors were labeled as rectal if located in the rectum or rectosigmoid junction.
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Sample Receipt and Processing
We requested colorectal tumor specimens from all population-based, case probands 
recruited in 1997-2002 as well as their CRC-affected first, second and third degree relatives. 
This provided a total of 3,970 specimens, out of which we received 3,732 (94%) formalin-
fixed, paraffin-embedded (FFPE) tissues. Specifically, we received two unstained 5-micron 
tissue sections embedded in paraffin from each tumor on positively charged “plus” glass 
slides without coverslips.
Slides were randomized to avoid batch effects attributed to source site and reagents. We 
deparaffinized each slide, microdissected tumor tissues and extracted genomic DNA as 
previously described (32). Proteinase K was inactivated by heating at 100°C for 10 min. An 
aliquot was then removed for bisulfite conversion using the Zymo EZ-96 DNA methylation 
kit (Zymo Research, Irvine, CA) as specified by the manufacturer. CIMP status in each 
sample was determined using a five-gene MethyLight-based signature (CACNA1G, IGF2, 
NEUROG1, RUNX3 and SOCS1) described previously (23). All MethyLight CIMP assays 
were performed using a control reaction specific for ALU repeats as a means of normalizing 
for input bisulfite-DNA amounts. MethyLight data were organized as Percent of Methylated 
Reference (PMR) value. Tumors were classified as CIMP if ≥3 of 5 genes gave PMR≥10, 
and non-CIMP if ≤2 genes gave PMR≥10, as described previously (23). Out of the 3,732 
samples processed, 46 (1.2%) failed the assay. For a subset of 25 tumors with two 
independent samples analyzed, 24 pairs were concordant for non-CIMP and 1 pair was 
discordant. In later analyses, the tumor with discordant results was classified as CIMP.
The processed samples yielded a total of 3,660 CRCs with CIMP results: 3,544 primary 
CRCs from case probands and 116 CRCs from affected relatives. Associations between 
tumor CIMP status and demographic, molecular, and environmental risk factors were 
performed using the population-based CRC samples from case probands. Of these primary 
CRCs, 108 case probands (3.0%) were excluded for having been interviewed more than 5 
years after diagnosis, 203 (5.7%) for missing RFQ data, and 104 (3.2%) for missing tumor 
site data or sampling weights (described in statistical methods section). The final analysis 
included 3,119 primary CRCs. The CIMP results for the 116 tumors from affected relatives 
were used to study the concordance for CIMP in tumors from affected relatives.
KRAS and BRAF Mutation Testing
The somatic T>A mutation at nucleotide 1799 causing the V600E mutation in BRAF was 
determined using a fluorescent allele-specific PCR assay that amplified a 97bp product for 
the mutant allele (A1799) and a 94bp product for the wildtype allele (T1799), as previously 
described (33). Positive controls were run in each experiment and 10% of samples were 
replicated with 100% concordance. KRAS mutation analysis of codons 12 and 13 was 
performed using direct Sanger sequencing of a 169bp PCR amplified product as previously 
described (34). The larger amplicon size for KRAS analysis compared with BRAFV600E 
contributed to a slightly higher proportion of the FFPE tumor DNA samples failing to 
amplify for the KRAS assay compared with BRAFV600E assay.
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MSI was tested using DNA from tumor and matched normal tissue as described in (35) 
using 10 microsatellite loci (BAT25, BAT26, BAT40, BAT34C4, D5S346, D17S250, 
ACTC, D18S55, D10S197, and MYCL). Samples were classified as MSI-H if > 30% 
showed instability, MSS if no markers showed instability and MSI-L otherwise. Tumor 
classification was based on ≥4 interpretable markers.
Statistical methods
Contingency tables present the frequency of patient and tumor characteristics by tumor 
CIMP status. All analyses were weighted based on the (inverse) sampling probability that 
the case proband was recruited into the registry to ensure the numbers represent the entire 
population of CRC cases at each study site. Subjects were included from all sites except 
Hawaii, because their sampling design precluded this type of weighted analysis. Frequencies 
are based on the weighted number of tumors in each category.
We tested for differences in distributions of individual risk factors by CIMP status using a 
case-case analysis. Case-case odds ratios (ccOR) and 95% confidence intervals (CI) were 
estimated using standard logistic regression, with weights to correct for sampling bias. 
These ccOR’s represent the relative odds for the risk factor in CIMP CRC compared to that 
in non-CIMP CRC and cannot be interpreted in terms of the magnitude of the risk for either 
tumor phenotype (36). The case-case analysis was the most powerful for testing etiologic 
heterogeneity of tumor subtype since it was not affected by heterogeneity due to the 
recruitment and use of different control types (related or unrelated) by different C-CFR 
centers. Models were stratified by sex, and adjusted for age and tumor site. Analyses of 
proximal tumors only yielded similar results, as the low numbers of CIMP in distal and 
rectal tumors precluded our ability to estimate separate ccORs by tumor site. We tested 
linear trend by modeling the levels of the ordered categorical variable as continuous. 
Interaction p-values were obtained by including interaction terms (e.g. sex*pack-year 
category) in the model and using a multiple degree of freedom test. Statistical significance 
was defined as a Wald test p-value < 0.05 in a two-sided test. All statistical analyses were 
performed using SAS 9.3 software (SAS institute Inc.).
Results
Characteristics of Study Population
After weighting, the 3,119 CRC patients in this study represented an estimated 6,253 
colorectal cancer cases. The estimated frequency of CIMP CRC was 12.6%, with 
frequencies ranging from 7% to 18% depending on the CCFR study population 
(Supplemental Table 1). CIMP CRC was associated with increased patient age (p<0.0001) 
and Australia and USC, the study populations with the lowest frequencies of CIMP CRC 
also had the lowest averages for age of CRC diagnosis (data not shown). CIMP CRC 
frequency varied by sex (16.8% in females versus 9.3% in males, p=0.0001) and was 
statistically significantly associated with location in the proximal colon in both males and 
females (Table 1). In addition, we observed variation in CIMP prevalence by race 
(Supplemental Table 1). In African Americans the CIMP prevalence was 4.5% and in 
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Asians it was 4.0%, compared to 13.4% in non-Hispanic Whites and 12.3 % in Hispanics. 
CIMP prevalence was significantly lower in African Americans (p=0.0098) and Asians 
(p=0.0182).
Association of CIMP status with BRAF mutation, KRAS mutation, and microsatellite 
instability
In screening for known KRAS and BRAF mutations in the sample cohort, we found a high 
frequency of the BRAFV600E mutation for CIMP proband tumors (63.8%), but not non-
CIMP proband tumors (2.1%) (Supplemental Table 1). KRAS mutations were more 
prevalent for non-CIMP compared to CIMP CRC (33.3%, versus 21%) (p < 0.0001). These 
associations remained significant after controlling for age, sex and tumor site (adjusted 
ccOR = 59.8, 95% CI=45.8-78.0 for BRAF and adjusted ccOR = 0.44, 95% CI 0.35-0.54 for 
KRAS). There was a strong mutual-exclusivity of BRAF and KRAS mutations in the tumor 
cohort, with only two CIMP CRC and one non-CIMP CRC displaying mutations in both 
genes. This could be explained for CIMP CRC by variations in BRAF and KRAS mutation 
frequency by age. BRAFV600E mutation frequencies for CIMP CRC were 36%, 59%, and 
75% in patients diagnosed at <50, 50-69, and >70 years. KRAS mutation frequencies for the 
same subgroups were 26%, 29%, and 10%. For CIMP CRC 58.7% were MSI-H, 11.2% 
MSI-L and 30.2% MSS. For non-CIMP tumors these figures were 10.7% MSI-H, 17.8% 
MSI-L and 71.5% MSS.
The associations between CIMP status and BRAF, KRAS and MSI-H were stronger for 
females than males (Table 1, all interaction p<0.0012). The BRAFV600E mutation occurred 
in 77.3% of CIMP CRC for females and 45.4% of CIMP CRC for males; KRAS mutation 
appeared in only 11.3% of CIMP CRC for females versus 34.3% of the same for males; and 
MSI-H occurred in 68.4% of CIMP CRC for females versus 43.2% of the same for males. 
KRAS mutation data was missing for 16.7% of CIMP CRC and 20% non-CIMP CRC 
(p=0.0017) (Supplemental Table 1).
Association of CIMP with known risk factors of colorectal cancer
Using the available clinical history and lifestyle information, we next determined if CIMP 
correlated with known CRC risk factors, including smoking history, alcohol use, physical 
activity, BMI and family CRC history (Table 2). A CIMP CRC was negatively correlated 
with family history for both men and women (both p<0.001), occurring more often in cases 
without a family history of CRC. However, only two of the 94 CRC affected relative pairs 
(2%) were concordant for CIMP CRC and 16 were discordant (17%) (Supplemental Table 
1). Limited in power and not statistically significant, this reflected a 2-fold higher frequency 
of CIMP CRC for affected relatives of a proband with CIMP CRC compared to a proband 
with non-CIMP CRC (25% vs 12%).
We found associations of CIMP status with smoking and BMI only for female cases 
(interaction p=0.0002 and 0.0001, respectively). We observed a significant trend of 
increased frequency of smoking in women with CIMP CRCs compared to those with non-
CIMP CRCs (Ptrend = 0.0001); no such association was observed for men (Ptrend=0.18). 
With respect to BMI, CIMP was inversely associated with overweight status for men (BMI: 
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25-29.9), but there was not a significant trend across BMI groups, Ptrend = 0.13. For female 
cases, both the overweight (P = 0.03) and obese (P = 0.0001) groups showed an increased 
frequency of having CIMP CRCs and the trend was significant (Ptrend = 0.0001). Alcohol 
use did not show heterogeneity by CIMP subgroup in men with CRC, but alcohol use in 
women presented lower frequencies of CIMP CRCs (Ptrend = 0.01). In general, men and 
women who engaged in higher levels of physical activity showed lower frequencies of 
CIMP CRCs (Heterogeneity P = 0.01; Supplemental Table 1).
Association of CIMP with pre-diagnosis use of vitamin supplements, NSAIDs and hormone 
therapies
We also evaluated use of multivitamins, calcium supplements and NSAIDs prior to CRC 
diagnosis in CIMP and non-CIMP cancers for men and women separately, and use of 
hormone replacement therapies by CIMP in women with CRCs (Table 3). Multivitamins or 
calcium supplement were not associated with CIMP subtype for men or women, however, 
men and women who used NSAIDs prior to diagnosis showed an increased frequency of 
CIMP CRC (P = 0.0001 for men; P = 0.02 for women; Table 3) The association between 
CIMP status and NSAID use varied between men and women (Pinteraction = 0.0008). The 
small increase in the frequency of CIMP CRC with HRT use for women was not statistically 
significant (P= 0.17).
Discussion
The global health concern regarding CRC necessitates an understanding of the contributions 
of family history and modifiable risk factors to the onset of disease. Since CRC can be 
classified into different molecular groups, we were specifically interested in whether CIMP 
CRC, as defined by DNA methylation analyses, is differentially associated with lifestyle, 
obesity status and/or family history compared to CIMP-negative tumors. We took advantage 
of the extensive sample collection of the C-CFR, together with patient information, to 
determine how CIMP status correlates with known CRC risk factors in a large population-
based setting. In this case-case analysis, associations between risk factor and CIMP status 
indicate etiologic heterogeneity between CIMP and non-CIMP tumors and does not inform 
us on direction of risk relative to non-diseased individuals. Furthermore, lack of association 
suggests no evidence of etiologic heterogeneity between the cancer subtypes.
Our data are in general agreement with previous reports that CIMP was more common in 
women with CRC, patients with later age of diagnosis, and CRC located in the proximal 
colon (22,23,25,26). Furthermore, our data showed that CIMP CRC occurred more often for 
patients without a family history of CRC, and that modifiable risk factors may contribute 
differentially to CIMP tumor development. Several risk factors showed different 
distributions in CIMP and non-CIMP tumors, with some of the associations modified by 
gender. For instance, smoking was associated with frequency of CIMP positive tumors for 
women, but not men. There was also a significant gender difference for the association 
between CIMP status and NSAID use. Finally, while CIMP was non-significantly inversely 
correlated with BMI for men, both overweight and obese statuses were positively correlated 
with CIMP status for women with a significant trend as BMI increases. These differences 
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may not be due to female hormones in this population given that a history of hormone 
replacement therapy was not significantly associated with CIMP status.
Our data show significant variation in smoking by CIMP status in women, but not in men, 
with CRC. This agrees with the results of other studies (9,21). In a women-only study, age-
related methylation of CpG islands in normal mucosa was confined to the proximal colon in 
the presence of smoking (29). However, Worthley et al. reported no difference in 
methylation status of a panel of CIMP markers in the normal colon between smokers and 
non-smokers when looking in men and women combined (37). Given our results, the 
analysis of the smoking/tumor phenotype association separately by gender is indicated.
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are protective against 
colorectal neoplasia (38). In a recent study of normal colorectal tissues from women, the use 
of aspirin and HRT resulted in suppressed rates of DNA methylation gain at sites commonly 
hypermethylated in CRC (29). In a study of advanced serrated polyps, the acknowledged 
precursors of CIMP CRC, aspirin was associated with a decreased risk of developing these 
lesions in the proximal colon (39). In our population, NSAID use was significantly more 
frequent in CIMP CRC than non-CIMP CRC for both men and women, suggesting that 
NSAID use is either not as protective against CIMP CRCs as it is for non-CIMP CRC or it 
increases risk of CIMP CRC. Slattery et al. reported significant protective effects for 
NSAIDs that were similar for both CIMP-low (0 or 1 marker methylated) and CIMP-high 
tumors (>2 of 5 markers methylated) (40). The CIMP markers used in that study were 
substantially different from ours, and there were notable differences between these two 
marker sets in a study comparing them directly (23). In our study, NSAID use was missing 
for more study participants with CIMP CRCs than with non-CIMP CRCs (6% vs 2%), 
which if not missing at random, could introduce some bias in our reported frequencies. 
Whether NSAID use affects CRC risk differently for the CIMP subset of tumors, and a 
possible interaction with gender, needs to be assessed in more study populations before any 
conclusions can be drawn.
Subsequent to this study, CIMP has been subcategorized into two groups, CIMP-High 
(CIMP-H) and CIMP-Low (CIMP-L). In addition, the CIMP2 subgroup was also identified, 
which has similarities to CIMP-L tumors (41). CIMP-H is representative of classic CIMP, 
with MSI-H, the BRAFV600E mutation and extensive DNA hypermethylation of a subset of 
CpG islands (25,26). Alternatively, CIMP-L tumors, first described by Ogino and colleagues 
(42), display attenuated DNA methylation of CIMP-defining loci, but these tumors are 
enriched for KRAS mutations, and are generally chromosome stable. Recently, The Cancer 
Genome Atlas (TCGA) reported CIMP-H in ~15% of colorectal tumors, the majority of 
which also showed elevated mutation rates (hypermutated) and few somatic copy number 
alterations (25). The MethyLight panel used here is analogous to the CIMP-H subtype. 
While our study did not characterize CIMP-L status, previous findings demonstrating the 
non-association of CIMP-L with smoking in colorectal tumors are intriguing, and may 
suggest that there are molecular features altered between CIMP-H and CIMP-L tumors that 
may help to explain these different relationships.
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Although BRAF mutation and MLH1 DNA hypermethylation are both highly associated 
with CIMP, only 64% of CIMP tumors harbored the BRAFV600E mutation and about 50% 
were MSI-H. Small differences from frequencies in other studies might be explained by a 
different average age of diagnosis (43-48). This suggests that the use of MSI-H status, 
MLH1 DNA methylation or BRAF mutation status as a surrogate for CIMP will result in 
misclassification of CIMP status. Also, several CIMP marker panels have been developed 
since the initial Toyota report in 1999 (22), and although the five-gene CIMP panel used in 
our study was chosen as a definitive panel, reports using other panels have been published 
(28,49). Sensitivities and specificities may differ between panels, contributing to varying 
CIMP calls. In addition, these findings have some implications for understanding which 
types of serrated polyps give rise to CIMP CRC. Though the canonical serrated neoplasia 
pathway has its foundation in the BRAF-mutated sessile serrated adenoma/polyp, other 
pathways to malignant transformation are needed to explain the diversity of CIMP CRC 
subtypes in this study, including KRAS-mutated CIMP CRC which has been previously 
thought to be rare (23,50). Some of the non-BRAF-mutated CIMP CRC may harbor 
mutations in PIK3CA (51).
The strengths of our study include its large size and population-based sample, and the use of 
a set of well-characterized markers to define CIMP status, thereby minimizing 
misclassification. The risk factor data were standardized across the different tumor 
collection sites using validated questions. However, we did not characterize associations 
with respect to CIMP-L status. To the extent that risk factors for CIMP-L cases are similar 
to those for CIMP-H we will have underestimated associations by including exposed CIMP-
L cases in the non-CIMP group. However, we cannot predict the direction of bias in cases 
where risk factors for CIMP-L are significantly different from those for CIMP-H. Future 
studies should evaluate associations of risk factors with CIMP-L once validated marker 
panels are developed.
In conclusion, we have utilized the large, population-based inventory of primary colorectal 
tumors from the C-CFR to analyze the associations between common CRC risk factors and 
tumor CIMP status to assess etiologic heterogeneity in cancer subtypes. The findings in this 
study show differential lifestyle and risk factor contributions to a subset of colorectal tumors 
with unique molecular characteristics.
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